SCHEMBL3267907

SCHEMBL3267907

Cc1ccc(CS(=O)(=O)CC(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.69
POLB P06746 4/20 0.49
ALDH1A1 P00352 5/20 0.47
RECQL P46063 2/20 0.47
ESR1 P03372 1/20 0.47
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
ESR2 Q92731 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47
MMP12 P39900 1/20 0.45
MMP13 P45452 1/20 0.45
HSD11B1 P28845 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13215735 0.85 KMT2A (0.59) KMT2APOLBALDH1A1LMNACYP3A4
SCHEMBL2338220 0.82 CA2 (0.52) KMT2APOLBALDH1A1ESR1ESR2
SCHEMBL498617 0.82 ALDH1A1 (0.56) POLBALDH1A1MMP12MMP13TSHR
SCHEMBL13870211 0.81 KMT2A (1.00) KMT2APOLBALDH1A1APEX1CYP3A4
SCHEMBL4400952 0.81 KMT2A (0.62) KMT2APOLBALDH1A1LMNACYP3A4
SCHEMBL3237371 0.81 TSHR (0.56) KMT2APOLBALDH1A1MMP12MMP13
SCHEMBL2337040 0.81 KMT2A (0.46) KMT2APOLBALDH1A1MMP12MMP13
SCHEMBL1137128 0.81 LMNA (0.47) KMT2APOLBALDH1A1LMNAMMP12
SCHEMBL831127 0.81 KMT2A (0.51) KMT2APOLBLMNAMMP12MMP13
SCHEMBL2338295 0.81 KMT2A (0.46) KMT2APOLBALDH1A1MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1292308-B1 ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2010-06-09 EP disclosed
EP-1292308-A4 ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2005-09-14 EP disclosed
US-6599932-B1 Highly selective in killing tumor cells but not normal cells TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2003-07-29 US disclosed
US-20030130339-A1 ALPHA, BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS REDDY E PREMKUMAR (US) 2003-07-10 US disclosed
US-6541475-B2 2-nitrostyryl-1-(naphthylmethyl)sulfone for example TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2003-04-01 US disclosed
EP-1292308-A1 ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS Temple University of the Commonwealth System of Higher Education (US) 2003-03-19 EP disclosed
US-20020028818-A1 Alpha, beta-unsaturated sulfones for treating proliferative disorders TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-03-07 US disclosed
WO-2001078733-A1 ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028818-A1 Alpha, beta-unsaturated sulfones for treating proliferative disorders QSOX1, CBR1, DEGS1 KMT2A 3686/4885POLB 749/4885ALDH1A1 738/4885
US-20030130339-A1 ALPHA, BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS QSOX1, CCNY, CBR1 KMT2A 3637/4885POLB 815/4885ALDH1A1 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.